Clinical Trial

Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd Clinical Study

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2025) - Celly Nutrition Corporation (the "Company" or "Celly Nutrition"), the company behind…

11 months ago

Rakuten Medical Completes Technology Transfer of IR700 Manufacturing and Establishes Exclusive Position in its Supply

IR700, a light-activatable dye, is a key component of the Alluminox™ platform-based photoimmunotherapyIR700 is being investigated in several other therapeutic…

11 months ago

CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares

Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

11 months ago

Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR

GenAI-powered solution delivers clinical study reports in minutes with 30%–50% faster turnarounds, 90% ICH-E3-aligned accuracy, and substantial cost savings. BERKELEY…

11 months ago

Movano Health Commences Clinical Study with New Cuffless Blood Pressure Device

New proprietary RF hardware delivers significantly enhanced signal fidelity PLEASANTON, Calif., Feb. 4, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE)…

11 months ago

Biospecimen Management Consortium Accelerates Growth, Releases Landmark Industry Survey, and Launches Key Initiatives

Amgen, Astellas, BioNTech, BMS, Day One, Debiopharm, Genmab, Halda, Inhibrx, Lilly, MSD, Profound Research, Replimune, and UPMC Hillman Cancer Center…

11 months ago

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced…

11 months ago

Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

Regulatory approval follows FemaSeed U.S. FDA-clearance announced September 2023 and EU CE mark approval announced June 2024ATLANTA, Feb. 04, 2025…

11 months ago

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

11 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE)…

11 months ago